KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Cash from Financing Activities (2016 - 2026)

Bio-Rad Laboratories has reported Cash from Financing Activities over the past 18 years, most recently at -$44.0 million for Q1 2026.

  • Quarterly Cash from Financing Activities rose 54.96% to -$44.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$229.5 million through Mar 2026, up 27.49% year-over-year, with the annual reading at -$283.2 million for FY2025, 29.43% down from the prior year.
  • Cash from Financing Activities was -$44.0 million for Q1 2026 at Bio-Rad Laboratories, down from $3.3 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $1.2 billion in Q1 2022 and troughed at -$202.7 million in Q2 2023.
  • The 5-year median for Cash from Financing Activities is -$69.5 million (2022), against an average of $125000.0.
  • The largest YoY upside for Cash from Financing Activities was 2613.98% in 2022 against a maximum downside of 4334.76% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at -$86.6 million in 2022, then crashed by 131.62% to -$200.6 million in 2023, then soared by 86.94% to -$26.2 million in 2024, then soared by 112.6% to $3.3 million in 2025, then tumbled by 1433.33% to -$44.0 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Cash from Financing Activities are -$44.0 million (Q1 2026), $3.3 million (Q4 2025), and -$52.5 million (Q3 2025).